FDA targets illegal pharma websites - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
FDA targets illegal pharma websites


Pharmaceutical Technology Europe

The FDA has issued 22 Warning Letters to website operators as part of its International Internet Week of Action, a week-long international effort aimed at curbing illegal actions involving medical products. Twenty-four countries participated in the special operation, which focused on four key areas:

  • increasing public awareness about the dangers and risks associated with purchasing drugs and medical devices online
  • identifying producers and distributors of counterfeit and illegal pharmaceutical products and medical devices
  • targeting these individuals and businesses with civil or criminal action
  • seizing counterfeit and illegal products and removing them from the supply chain.

"Many U.S. consumers are being misled in the hopes of saving money by purchasing prescription drugs over the Internet from illegal pharmacies," said FDA Commissioner Margaret A. Hamburg in a press statement. "Unfortunately, these drugs are often counterfeit, contaminated, or unapproved products, or contain an inconsistent amount of the active ingredient. Taking these drugs can pose a danger to consumers."

The FDA’s Office of Criminal Investigations, Center for Drug Evaluation and Research, Office of Regulatory Affairs, and Office of Enforcement were involved in the effort, which targeted 136 websites that "appeared to be engaged in the illegal sale of unapproved or misbranded drugs to US consumers", according to the release. The effort was sponsored by the International Criminal Police Organization, the World Health Organization's International Medical Products Anticounterfeiting Task Force, the Permanent Forum on International Pharmaceutical Crime, and the national health and law enforcement agencies of the 24 participating countries.

www.fda.gov

Read related blogs at:

Report: Online Drug Brand Abuse on the Rise
FDA’s Recent Actions Against Illegal Prescription Drug Flow

ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What factor do you think will be most significant in 2010 for determining the health of the market for contract manufacturing of active pharmaceutical ingredients?
The global economic recovery
The US economic recovery
Improved credit and financing flow to the small to emerging pharma/bio sector
Less restrictive inventory control by pharmaceutical companies
The level of competition from contract manufacturers in emerging markets
The global economic recovery
40%
The US economic recovery
13%
Improved credit and financing flow to the small to emerging pharma/bio sector
15%
Less restrictive inventory control by pharmaceutical companies
8%
The level of competition from contract manufacturers in emerging markets
23%
View Results
Eric LangerOutsourcing OutlookEric Langer A Bio View of Outsourcing
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advances in Custom Synthesis
Faiz kermaniSpotlightFaiz Kermani EU pricing dilemmas
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
NSF, Microsoft Team in Cloud Computing
Keep an eye on that cargo
Pharma packs a punch
Another Boost for Vaccines
Rodney Dangerfield and R&D
FindPharma Custom Search
Source: Pharmaceutical Technology Europe,
Click here